Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?

Pedro Luiz Serrano Uson Junior, Bolni Marius Nagalo, Daniel H. Ahn, Tanios Bekaii-Saab, Mitesh J. Borad

Research output: Contribution to journalArticlepeer-review


The past decade has seen a rise in the availability of breakthrough therapeutic strategies for treatment of hepatocellular carcinoma (HCC). A tumor microenvironment in HCC is regulated by various immunotolerance mechanisms; therefore, therapeutic strategies aiming at disrupting tumor immune tolerance are becoming attractive curative options in HCC. Immune checkpoint inhibitors have demonstrated impressive effectiveness in HCC, including in sorafenib-unresponsive patients. Synergistic approaches with checkpoint inhibitors (anti-PD-1/PD-L1 and CTLA-4) and antiangiogenic drugs are burgeoning as first-line treatment therapeutic modalities in HCC.

Original languageEnglish (US)
Pages (from-to)136-141
Number of pages6
JournalSeminars in liver disease
Issue number2
StatePublished - May 1 2021


  • anti-CTLA-4
  • anti-PD-1
  • checkpoint inhibitors
  • hepatocellular carcinoma
  • liver

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?'. Together they form a unique fingerprint.

Cite this